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Human Vg9Vd2 T cells respond to tumor cells by
sensing elevated levels of phosphorylated intermedi-
ates of the dysregulated mevalonate pathway, which
is translated into activating signals by the ubiqui-
tously expressed butyrophilin A1 (BTN3A1) through
yet unknown mechanisms. Here, we developed an
unbiased, genome-wide screeningmethod that iden-
tified RhoB as a critical mediator of Vg9Vd2 TCR acti-
vation in tumor cells. Our results show that Vg9Vd2
TCR activation is modulated by the GTPase activity
of RhoB and its redistribution to BTN3A1. This is
associated with cytoskeletal changes that directly
stabilize BTN3A1 in the membrane, and the subse-
quent dissociation of RhoB from BTN3A1. Further-
more, phosphoantigen accumulation induces a
conformational change in BTN3A1, rendering its
extracellular domains recognizable by Vg9Vd2 TCRs.
These complementary events provide further evi-
dence for inside-out signaling as an essential step
in the recognition of tumor cells by a Vg9Vd2 TCR.
INTRODUCTION
gdT cells are unconventional T cells with strong reactivity toward
a broad spectrum of tumors of diverse tissue origin. gdT cells
combine potent anti-tumor effector functions with the recog-
nition of broadly expressed tumor-associated molecules, and
these features have put gdT cells in the spotlight for clinical appli-
cation in cancer immunotherapy. Activation of gdT cells involves
the sensing of metabolic changes in cancer cells that result in the
expression of generic stress molecules. These molecules are
upregulated upon transformation or distress (Bonneville et al.,
2010; Vantourout and Hayday, 2013). However, progress in theCe
This is an open access article undclinical application of gdT cells for cancer treatment is hampered
by conflicting published data from various labs that describe
contradicting molecular requirements for gdT cell activation
(Scheper et al., 2014; Vavassori et al., 2013; Sandstrom et al.,
2014) as well as by a lack of prognostic markers to assess which
patients may benefit from such therapy.
Vg9Vd2 T cells, the major gdT cell subset in human peripheral
blood, express gdT cell receptors (TCR) composed of Vg9 and
Vd2 chains and are specifically activated by intermediates of
the mammalian mevalonate pathway (Gober et al., 2003; Con-
stant et al., 1994), such as isopentenyl pyrophosphate (IPP),
or by the microbial 2-C-methyl-D-erythritol 4-phosphate (MEP)
pathway (Morita et al., 2007). Intracellular phosphoantigen
(pAg) levels accumulate in tumor cells due to dysregulation
of the mevalonate pathway or upon microbial infection, allowing
the targeting of transformed or infected cells by Vg9Vd2 T cells.
Similarly, intracellular phosphoantigen levels can be pharmaceu-
tically increased by treating cells withmevalonate pathway inhib-
itors such as aminobisphosphonates (ABPs), thereby sensitizing
cells toward recognition by Vg9Vd2 T cells. Although the involve-
ment of the Vg9Vd2 TCR in detecting elevated phosphoanti-
gen levels was demonstrated as early as the 1990s (Bukowski
et al., 1998; Davodeau et al., 1993;Wang et al., 2010), themolec-
ular determinants required for activation of Vg9Vd2 TCRs on
target cells have long remained elusive.
Although recent breakthrough studies have identified the
membrane-expressed butyrophilin BTN3A1 (CD277) as a key
molecule in phosphoantigen-induced activation of Vg9Vd2
T cells, (Harly et al., 2012; Sandstrom et al., 2014; Vavassori
et al., 2013), they describe conflicting molecular roles for
BTN3A1 in the Vg9Vd2 T cell activation process. While Vavassori
et al. (2013) suggest that BTN3A1 as antigen presenting mole-
cule triggers Vg9Vd2 T cell activation, data from Sandstrom
et al. (2014) andHarly et al. (2012) support an inside-out signaling
mechanism for BTN3A1, where phosphonatigens bind to its
intracellular region and in which model immobilization of
BTN3A1 at the cell surface may contribute to an extracellularll Reports 15, 1973–1985, May 31, 2016 ª 2016 The Authors. 1973
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cue for recognition by Vg9Vd2 TCRs. Since BTN3A1 is ex-
pressed on both transformed and healthy human cells (Compte
et al., 2004), additional molecules are likely involved in medi-
ating selective recognition of tumor targets by Vg9Vd2 T cells,
including; e.g., the cytoskeletal adaptor protein Periplakin (Rho-
des et al., 2015). However, it is unclear how these different
proposed molecules and mechanisms are linked. Here, we
developed an unbiased, genome-wide screening method,
SNP-Associated Computational Pathway Hunt Including short
hairpin RNA (shRNA) Evaluation (SAPPHIRE), and identified
important molecular requirements for Vg9Vd2 T cell-mediated
recognition of cancer (stem) cells.We propose a two-component
mechanism occurring in a tumor cell, which allows Vg9Vd2
T cells to specifically sense cellular transformation.
RESULTS
Identification of Genetic Loci Associated with Vg9Vd2
TCR-Mediated Target Cell Recognition by SNP-
Associated Computational Pathway Hunt Including
shRNA Evaluation
We hypothesized that differences in the genetic backgrounds of
tumor cells affect recognition of these cells by Vg9Vd2 TCR-engi-
neered T cells. Therefore, we utilized the library of cell lines from
the Centre d’Etude du Polymorphisme Humain (CEPH), which
contains a large collection of EBV-transformed B cell lines
(EBV-LCLs) obtained from several family pedigrees (Dausset
et al., 1990) and genotyped for millions of SNPs (International
HapMap Consortium, 2003). CD4+ abT cells engineered to ex-
press one defined Vg9Vd2 TCR were utilized for the functional
screening in order to eliminate fluctuations in recognition by a
diverse gdTCR repertoire (Gr€under et al., 2012) and varying
expression of natural killer (NK) receptors (Scheper et al.,
2013; Correia et al., 2013). The recognition phenotypes of EBV-
LCLs by Vg9Vd2 TCR T cells were assessed by means of inter-
feron (IFN) g production and showed an activating phenotype
for 33 EBV-LCLs, while 7 were non-activating (Figures S1A and
S1B). Importantly, in the zygocity analysis, EBV-LCLs with a
non-activating phenotype represent more power than those
with an activating phenotype analyzed with SAPPHIRE. Hypo-
thetical zygosities for candidate genetic loci were deduced using
classical Mendelian inheritance patterns within CEPH family
trios, where the influence of candidate alleles on Vg9Vd2 TCR-
mediated recognition was assumed to be dominant. The result-
ing recognition phenotypes combined with family pedigrees of
the CEPH cell lines overcame the need to screen large numbers
of LCL lines (Spaapen et al., 2008), and allowed the precise pre-
diction of zygosities of candidate loci for 12 CEPH individuals
(Figure 1A). The hypothetical loci zygosities were then correlated
with available genotype information of SNPs within the study’s
population (Spaapen et al., 2008), resulting in the identifica-
tion of 17 SNPs whose genotypes correlated perfectly (100%)
with predicted zygosities (Figure 1B). Since none of these 17
SNPs, nor their proxy SNPs within high linkage disequilibrium
(r2 > 0.8), directly affected genes by causing changes in protein
coding sequences, we speculated that rather than playing direct
roles, the SNPs we identified could represent surrogate markers
for genetic regions associated with susceptibility to Vg9Vd21974 Cell Reports 15, 1973–1985, May 31, 2016TCR+ T cell recognition. In addition, we queried the genomic vi-
cinity of the17SNPs for neighboringcandidate genes (Figure 1C).
To test the relevance of these genes for Vg9Vd2 TCR+ T cell-
mediated target recognition, we knocked down all 17 SNP-adja-
cent genes in the Vg9Vd2 TCR+ T cell-activating EBV-LCL line
48. We then assessed the effect of knockdown on activation
of Vg9Vd2 TCR+ T cells by measuring IFN-g production, which
was reduced upon the knockdown of three genes (RAB4A,
RHOB and UBE3C) (Figure 1B). To ensure that potential knock-
down effects pointed to genes that selectively affect Vg9Vd2
TCR-dependent activation, the three knockdown variants of
EBV-LCL line 48 were pulsed with Wilm’s tumor 1 (WT1) peptide
and tested for recognition with T cells engineered to express the
cognate WT1-specific abTCR (Kuball et al., 2007). The selective
knockdown of the small GTPase RhoB significantly affected the
activation of Vg9Vd2 TCR- but not abTCR-engineered T cells
(Figure 1B). Similar data were observed after partial knockdown
of RhoB in the prototypic Vg9Vd2 T cell target cell line Daudi (Fig-
ure S2B), as well as after CRISPR/Cas-mediated partial RhoB
knockout in the renal carcinoma cell line MZ1851RC (Figure 2A).
Interestingly, even complete knockout of RhoB in 293 HEK cells
resulted only in partial depletion of target cell-mediated Vg9Vd2
TCR T cell activation (Figure S2A). In addition, knockout of either
RhoA or RhoC genes in 293 HEK cells did not significantly influ-
ence their ability to activate Vg9Vd2 TCR+ T cells (Figures 2B
and S2C), emphasizing that RhoB modulates the recognition of
tumor cells by a defined Vg9Vd2 TCR in a non-redundant role.
Target Cell Recognition by Vg9Vd2 TCRs Depends on
Rho GTPase Activity
Genomic sequencing of RhoB and associated promoter regions
did not identify genetic variations associated with our marker
SNP (data not shown), suggesting that RhoB is indirectly regu-
lated by other gene loci influencing expression or activity
(Pombo and Dillon, 2015). Our primary observations, however,
confirmed that neither RhoB RNA nor protein levels in various
recognized and two non-recognized tumor cell lines correlated
with their ability to activate Vg9Vd2 TCR+ T cells (Figures 2C,
S2D, and S2E). Therefore, we assessed the impact of RhoB
GTPase activity by pretreating different tumor cell lines with
either the Rho GTPase activator calpeptin or inhibitor C3 trans-
ferase (Aktories et al., 1992; Schoenwaelder and Burridge,
1999). Pretreatment with calpeptin significantly sensitized EBV-
LCL 93 cells for recognition by Vg9Vd2 TCR+ T cells while,
conversely, inhibition of Rho GTPase with C3 transferase
resulted in significantly reduced activation of Vg9Vd2 TCR+
T cells by LCL 48 cells (Figure 2D). Importantly, modulation of
Rho GTPase activity did not affect the recognition of WT1
peptide-pulsed EBV-LCL 48 cells by WT1 abTCR-transduced
T cells. To specify that enzymatic activity of RhoB regulates tu-
mor cell recognition by Vg9Vd2 TCR+ T cells, we transfected
HEK293 cells with wild-type or dominant-negative form corre-
sponding to the GDP-bound state (RhoB-DN), or with the consti-
tutively active form corresponding to the GTP-bound form
(RhoB-CA) of RhoB (Kamon et al., 2006) and used them as target
cells for Vg9Vd2 TCR+ T cells (Figure 2E). HEK cells overexpress-
ing RhoB-CA mutants were able to trigger significantly stronger
Vg9Vd2 TCR-specific responses than cells expressing wild-type
Figure 1. SNP-Associated Computational Pathway Hunt Including shRNA Evaluation to Identify Genetic Loci Associated with Vg9Vd2 TCR
Stimulation
(A) The recognition of CEPH EBV-LCL lines by Vg9Vd2 TCR+ T cells provided the basis for deducing hypothetical zygosities of candidate loci in each cell line
(black, recognized; white, not recognized; square, male; circle, female; +/, heterozygous; /, homozygous negative; +/?, undetermined). Members of two
CEPH families are shown as examples. For CEPH ID numbers of cell lines, see Figure S1A.
(B) Genetic association analysis revealed 17 SNPs of which genotypes correlated 100% (r2 = 1) with predicted zygosities of cell lines. Locations and nearest
neighboring genes of SNPs are indicated. The effect of knocking down candidate genes on recognition of EBV-LCL 48 by T cells transduced with either Vg9Vd2
TCR cloneG115 or anHLA-A*0201-restrictedWT1126–134-specific abTCR are indicated by black circles (significant effect on T cell activation) andwhite circles (no
effect). For testing recognition by WT1 abTCR+ T cells, the EBV-LCL 48 line was pulsed with WT1126–134 peptide.
(C) Associating SNPs resulting from association analysis with candidate genes. The genetic region of the SNPs neighboring RhoB is shown as an example. Each
bar represents one SNP, and r2 values represent correlation between predicted zygosities and SNP genotypes.RhoB, while RhoB-DN-transfected HEK cells showed a signif-
icantly reduced ability to stimulate Vg9Vd2 TCR+ T cells
compared to cells expressing wild-type RhoB. Thus, these
data suggest that the biochemical activity of RhoB GTPases is
a critical factor modulating the recognition of cancer cells by
Vg9Vd2 TCR+ T cells.
The Intracellular Distribution of RhoB in Cancer Stem
Cells Marks Susceptibility for Vg9Vd2 TCR-Mediated
Recognition
Rho proteins have been shown to translocate within cellular
compartments upon activation (Kranenburg et al., 1997). There-
fore, we hypothesized an impact on subcellular localization ofRhoB in recognized versus non-recognized cells. Additionally,
ABP treatment of cells have been demonstrated to increase
the GTP-bound forms of Rho GTPases (Dunford et al., 2006)
that could provide a possible link between dysregulation of me-
valonate pathway in tumor cells and RhoB cellular compartmen-
talization. This hypothesis was supported by confocal imaging,
which revealed that distribution of RhoB patches that were pri-
marily reported to locate to membranes of intracellular vesicles
such as endosomes (Adamson et al., 1992; Michaelson et al.,
2001), segregated strongly with the susceptibility of different
target tumor cell lines to Vg9Vd2 TCR-mediated recognition.
RhoB was selectively excluded from nuclear areas in cells that
are able to activate Vg9Vd2 TCR+ T cells (Figures 3A, 3B, S3A,Cell Reports 15, 1973–1985, May 31, 2016 1975
Figure 2. RhoB Activity Correlates with
Target Cell Recognition by Vg9Vd2 TCR+
T Cells
(A) RhoB was knocked out in the renal cancer cell
line MZ1851RC using the CRISPR/Cas system.
MZ1851RC cells were treated with either pamidr-
onate or HLA-A*0201-restricted WT1126–134 pep-
tide, and the effect on target cell recognition
by Vg9Vd2 TCR+ and WT1 abTCR+ T cells,
respectively, was determined by measuring IFN-g
production. A guide RNA targeting an irrelevant
sequence was used as control for knockout, while
medium or irrelevant peptide loaded tumor cells
were used as controls for T cell stimulation. Data
show mean ± SEM of three independent experi-
ments, in duplicate samples. Level of knockout
was determined by intracellular flow cytometry.
(B) The effect of knockout of RhoA, B, and C in 293
HEK cells on recognition by Vg9Vd2 TCR+ T cells
was assessed by measuring IFN-g production.
A guide RNA targeting an irrelevant sequence was
used as control. Figure shows IFN-g production
normalized to irrelevant knockout samples of three
independent experiments, in duplicate samples.
(C) RNA expression of RhoB was measured by
qPCR in either non-recognized (black bars) or
recognized (white bars) EBV-LCLs and tumor cell
lines. Data are representative of two repeated
experiments.
(D) The non-recognized EBV-LCL line 93 or the
recognized EBV-LCL 48 were pretreated with
either calpeptin or C3 transferase in combination
with pamidronate or IPP, and the effect on stimu-
lation of Vg9Vd2 TCR+ T cells was assessed by
measuring IFN-g. The effect of Rho-modulating
compounds on recognition of WT1126–134 peptide-
pulsed EBV-LCL 48 cells by WT1 abTCR+ T cells
was measured in parallel. Data show mean ± SEM
of at least three independent experiments.
(E) HEK293 cells were transfected with dominant-
negative (RhoB-DN), constitutively active (RhoB-
CA), or wild-type RhoB (RhoB-WT), and the effect
of activity variants on target cell recognition by
Vg9Vd2 TCR+ T cells in the presence of pa-
midronate was determined by measuring IFN-g.
Figure shows IFN-g production normalized to
wild-type RhoB samples of three independent
experiments.
The significance of data has been analyzed by
Mann-Whitney test in (A), (B), and (D) and by
Kruskal-Wallis test and Dunn’s multiple compari-
son test in (E).
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and S3E). Crucially, re-localization of RhoB from the nucleus, or
from the nuclearmembrane to extranuclear sites was induced by
ABP as well as by soluble phosphoantigen IPP in cell lines (Fig-
ures 3C and 3D), emphasizing that this process is dependent on
accumulation of intracellular phosphoantigen. Expressing trans-
genic RhoB-GFP in either recognized or non-recognized tumor
cell lines followed intracellular distribution of the endogenous
RhoB (Figure S3B), suggesting post-translational regulation of
RhoB. The homogenous intracellular distribution of other
GTPases such as RhoA did not change upon ABP treatment (Fig-
ure S3C), supporting the observation that RhoA knock down did
not impact Vg9Vd2 TCR-mediated recognition (Figure 2B). We
found that RhoB was excluded from the nucleus in human, but
not in mouse dendritic cells selectively treated with ABP, even
though RhoB protein sequences are identical in both species
(Figures 3E and S3D). This is consistent with our previous obser-
vations that human, but not mouse monocyte-derived dendritic
cells are able to activate Vg9Vd2 TCR+ T cells (Marcu-Malina
et al., 2011). In order to test whether redistribution of RhoB oc-
curs upon ABP treatment in leukemic cancer stem cells also,
we sorted leukemic blasts, cancer stem cells and healthy stem
cells from the very same donor based on flow markers (Terwijn
et al., 2014), and we quantified distribution of RhoB. Indeed, in
primary blasts from an acute myeloid leukemia patient/donor,
RhoB localization correlated with the recognition by Vg9Vd2
TCR-engineered T cells (Figures 3B and S3A) including leukemic
stem cells, but not healthy stem cells from the same donor (Fig-
ure 3F). This supports our previous observation that Vg9Vd2
TCR-mediated recognition selectively targets the leukemic but
not the healthy stem cell pool (Marcu-Malina et al., 2011). Taken
together, the intracellular distribution of the small GTPase RhoB
strongly correlates with recognition of diverse tumor targets,
including cancer stem cells, and exclusion of RhoB from the nu-
cleus is a signature of tumor cells that are susceptible for target-
ing by Vg9Vd2 TCR+ T cells.
RhoB Regulates Membrane Mobility of BTN3A1 on
Cancer Cells
Decreased mobility of the transmembrane protein BTN3A1 on
target tumor cells has recently been identified as a critical determi-
nantofVg9Vd2Tcell activation (Harlyetal., 2012;Sandstrometal.,
2014; Vavassori et al., 2013). However, the mechanisms linking
intracellular accumulation of phosphoantigens to changes in
BTN3A1 membrane mobility are unclear. Therefore, the impact
of ABPandRhoB, an important player in the cytoskeletal reorgani-
zation and formation of actin stress fibers (Prendergast, 2001), on
mobility of BTN3A1 was tested. Consistent with previous reports
(Harly et al., 2012; Sandstrom et al., 2014), treating 293 HEK cells
with the ABP zoledronate resulted in decreased BTN3A1 mem-
branemobility. Strikingly, treatment with calpeptin induced immo-
bilization of BTN3A1 to similar levels as those of ABP treatment
alone, whereas C3-transferase counteracted this ABP effect (Fig-
ure 4A). This points to the possibility that RhoGTPase activity acts
on BTNA1membrane immobilization upstream of the mevalonate
pathway. Selective depletion of RhoB by CRISPR/Cas inhibited
the ABP-induced immobilization of BTN3A1 to levels comparable
to those of medium controls, suggesting that ABP-mediated
changes in BTN3A1 mobility depend on RhoB.To next assess a role for RhoB-induced cytoskeletal rearrange-
ments inmediating the observedchanges inBTN3A1mobility, the
relation between BTN3 molecules and F-actin was investigated
by colocalization experiments. HEK293 cells were stained with
fluorescently labeled anti-BTN3andphalloidin, andcolocalization
coefficients were determined in response to treatment with ABP
andcalpeptin. Incells inaculturemedium,avariablebutconsider-
able colocalization betweenBTN3andF-actinwasobserved, and
was markedly reduced by ABP treatment (Figure 4B). Strikingly,
and similar to its effect on BTN3A1 membrane mobility, calpeptin
reduced colocalization betweenBTN3 and F-actin to comparable
levels observed with ABP treatment. This reduction suggests
that both phosphoantigen accumulation and Rho activation may
induce the formation of membrane domains surrounded by cyto-
skeleton, where BTN3 molecules could be trapped and immobi-
lized, as recently described for FcεRI (Andrews et al., 2008).
Importantly, C3-transferase prevented ABP-induced BTN3-actin
segregation, indicating again the crucial involvement of active
Rho in this process. Together, these data suggest that RhoB
activity contributes to target recognition by Vg9Vd2 TCR+ T cells
by modulating BTN3A1 membrane mobility through cytoskeletal
rearrangements.
RhoB Interacts with BTN3A1 Homodimers in Cancer
Cells Recognized by Vg9Vd2 TCRs
Given the strong requirement for RhoB activity in the membrane
immobilization of BTN3A1, we questioned whether regulation
of BTN3A1 involved direct interactions with RhoB. Using in situ
proximity ligation assay (PLA), RhoB and BTN3 were observed
to be in close proximity in recognized EBV-LCL 48 cells only
when pretreated with the ABP (Figure 5A). Importantly, PLA sig-
nals were typically excluded from the nuclear area and distrib-
uted close to the plasma membrane, in line with our data that
RhoB is involved in Vg9Vd2 TCR+ T cell recognition by regulating
membrane-expressed BTN3A1.
To determine whether BTN3A1 exists as a homodimer when
expressed in a cellular context, as suggested from crystallization
studies (Palakodeti et al., 2012), and to study RhoB-BTN3A1 in-
teractions at even higher resolution, we examined close interac-
tions by utilizing fluorescence resonance energy transfer (FRET).
Flow cytometry FRET measurements were performed on ABP-
sensitive HEK293 cells (Harly et al., 2012), by either overexpress-
ing FRET compatible fusion proteins or labeling endogenous
proteins with antibodies coupled to FRET-compatible fluoro-
chromes. These experiments showed that BTN3A1 molecules
are expressed as homodimers on the cell surface of cancer
cells (Figure 5B); however, the pairing of BTN3A1 molecules
was insensitive to ABP-induced phosphoantigen accumulation.
Close association betweenRhoBandBTN3A1was undetectable
in ABP-untreatedHEK cells but increasedmarkedly after treating
cells with the ABP (Figure 5C). We used Biolayer Interferometry
(BLI) to formally define a possible docking site for RhoB on the
intracellular domain of BTN3A1. RhoB binding was detected
with recombinant full-length BTN3A1 intracellular domain (BFI)
(Figure 5D, left, and Table S1) yet was significantly reduced
when using a recombinant BTN3A B30.2 domain, lacking the
N-terminal region connector to the transmembrane domain
(Figure 5E left). These data indicate an important role for theCell Reports 15, 1973–1985, May 31, 2016 1977
(legend on next page)
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Figure 4. RhoB Activity Modulates BTN3A1
Membrane Mobility and Its Association
with the Actin Cytoskeleton
(A) HEK293 cells were transfected with BTN3A1-
emGFP fusion constructs and treated with me-
dium, ABP zoledronate, or calpeptin. Zoledronate
treatment was also applied to HEK293 BTN3A1-
emGFP+ cells in which RhoB was knocked out by
CRISPR/Cas or in cells that were also treated with
C3-transferase. BTN3A1 mobility was measured
within selected membrane regions of interest
by subsequent photobleaching and fluorescence
recovery after photobleaching (FRAP) measure-
ment as described in the Supplemental Informa-
tion. The figure shows the percentage of BTN3A1
immobile fraction upon treatments applied (+).
Symbols represent single-cell measurements, of
two experiments.
(B) HEK293 cells were pretreated with pamidro-
nate or with calpeptin, and BTN3 molecules and
filamentous actin (F-actin) were stained using a fluorescently labeled anti-BTN3 antibody and fluorescent phalloidin, respectively. The colocalization of BTN3 and
F-actin was subsequently assessed by determining the localization correlation of both signals, as described in Experimental Procedures. Symbols represent
single-cell measurements, of a single experiment. The center line and error bars represent average and SEM; p values indicate significance analyzed by using
Mann-Whitney test.membrane proximal region of the BTN3A1 intracellular domain in
binding to RhoB GTPase. Interestingly, RhoB binding to BFI was
almost completely abolished in the presence of soluble phos-
phoantigen cHDMAPP (Figure 5D right).When in the sameexper-
iment, the physiologically more relevant but much lower affinity
pAg IPP was applied, BLI was unable to resolve pAg-induced
dissociation of RhoB from BFI (Figure S4C), very likely due to
the technical limitation of the assay. In summary, our data indi-
cate that RhoB and BTN3 molecules closely interact at the sur-
face membrane selectively in a Vg9Vd2-stimulatory context and
that the physical interaction is regulated by phosphoantigens.
Phosphoantigen Accumulation Associates with
Conformational Changes of BTN3A1 Dimers
Conformational changes of BTN3A1 in response to elevated
levels of phosphoantigens have been proposed to serve as aFigure 3. Intracellular Distribution of RhoB Correlates with the Recogn
(A) Non-recognized healthy T cells, leukemic cell line ML-I and EBV-LCL 93 cells,
LCL 48, and EBV-LCL 70 cells were treated with pamidronate and loaded onto po
stained using RhoB-specific antibody followed by an Alexa-Fluor 488-conjugated
microscopy, and representative images are shown (green, RhoB; blue, nucleus [
(B) T cells from healthy donors, EBV-LCL line 93, 48, and 70, tumor cell lines M
AML2905, and murine and human dendritic cells (DCs) were treated with pamid
croscopy. White bars represent target cells with a non-activating phenotype, whil
The RhoB signal ratio between nuclear and extranuclear cellular compartments
ratios of at least ten different cells ±SEM. Statistical significance compared to pe
and Dunn’s multiple comparison test.
(C) The intracellular RhoB distribution in recognized, ABP/IPP-sensitive EBV-LCL
(D) The RhoB signal ratio between nuclear and extranuclear cellular compartme
software. Graphs show average ratios of at least ten different cells ±SEM. Statist
Mann-Whitney test.
(E) The intracellularRhoBdistribution in thepresenceor absenceof ABPpamidrona
donors. Bone-marrow-derivedmouse dendritic cells (>95%CD11c+) were treated
average ratios of at least ten different cells ±SEM. Statistical significance compar
(F) CD34+CD38– leukemic stem cells were sorted from four patients of which le
recognized (AML 2907), respectively, and the ratios between extranuclear and nu
different cells ±SEM. Statistical significance compared to CD34+CD38– healthy sstimulatory signature for Vg9Vd2 TCRs (Palakodeti et al., 2012;
Harly et al., 2012; Sandstrom et al., 2014); however, no experi-
mental data have so far been reported to substantiate this hy-
pothesis. The crystal structures of the extracellular domain of
BTN3A1 in complex with the functionally well-characterized
BTN3-specific antibodies 20.1 and 103.2 (Harly et al., 2012)
have recently been resolved and have revealed that both anti-
bodies bind to different epitopes on the membrane-distal Ig-V
domains of BTN3A1 dimers (Figure 6A) (Palakodeti et al.,
2012). To study BTN3A1 conformational changes in response
to increased phosphoantigen levels, surface membranes of
either unstimulated or ABP-stimulated HEK293 cells were
labeled with the fluorescent lipid conjugate BODIPY FL (donor),
and subsequently stained with acceptor dye-labeled BTN3-
specific antibodies on ice, in order to prevent conformational
changes that could be driven by these antibodies underition of Target Cells by Vg9Vd2 TCR+ T Cells
and recognized leukemia cell line K562, colon carcinoma cell line SW480, EBV-
ly-L-lysine-coated coverslips. Attached cells were fixed and permeabilized and
secondary antibody. RhoB distribution was subsequently analyzed by confocal
DAPI]).
L-I, K562, SW480, Raji, primary AML blasts AML2913, AML2907, AML2889,
ronate and analyzed for the intracellular distribution of RhoB in confocal mi-
e black bars indicate target cells that are able to activate Vg9Vd2 TCR+ T cells.
was measured using ImageJ image analysis software. Graphs show average
ripheral blood lymphocyte (PBL) was determined by using Kruskal-Wallis test
48 was analyzed upon ABP pamidronate and soluble IPP as in (A).
nts in experiments shown in (C) was measured using ImageJ image analysis
ical significance compared to untreated EBV-LCL 48 was determined by using
tewasdetermined inmonocyte-derivedhumandendritic cells from twodifferent
with ABP pamidronate and used for intracellular labeling of RhoB. Graphs show
ed to LPS treated human DCs was determined by using Mann-Whitney test.
ukemic blasts were recognized (AML 2889, AML 1665, AML 2575) and non-
clear RhoB signal were measured. Graphs show average ratios of at least ten
tem cells was determined by using Mann-Whitney test.
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Figure 5. RhoB Interacts with BTN3 Molecules and Dissociates after Phosphoantigen Treatment
(A) EBV-LCL 48 cells were treated either with medium or ABP pamidronate, loaded onto poly-L-lysine-coated coverslips, and permeabilized. The interaction
between RhoB and BTN3was subsequently assessed by Duolink PLA using anti-RhoB and anti-CD277 antibodies. Duolink PLAwithout antibodies against RhoB
and BTN3 served as negative control (red, PLA signal; blue, nucleus [DAPI]; dotted line, cell membrane). Figures are representative of two independent
experiments.
(B) HEK293 cells were treatedwith either medium or pamidronate and co-stainedwith equal amount of anti-CD277-PE (donor) as well as anti-CD277-DyLight 680
(acceptor) antibodies, and FRET efficiency in cells was measured as described in the Supplemental Information. Data shown are mean ± SEM of three inde-
pendent experiments, in triplicate samples, where Mann-Whitney test was used to analyze statistical significance.
(C) HEK293 cells were pretreated either with medium or pamidronate, trypsinized, permeabilized, and stained with anti-RhoB-Alexa Fluor 488 (FRET donor) and
anti-CD277-DyLight 680 (FRET acceptor) antibodies. FRET efficiency was subsequently measured by flow cytometry as described in the Supplemental Infor-
mation. Data show mean ± SEM of three independent experiments, in triplicate samples, where Mann-Whitney test was used to analyze statistical significance.
(D) Concentration dependent binding of the full-length BTN3A1 intracellular domain (BFI) with RhoGTPase in the presence or absence of the phosphoantigen
cHDMAPP. Binding of BFI to RhoGTPase was measured using Biolayer Interferometry (BLI) either in the absence of cHDMAPP (left panel) or presence of
cHDMAPP (1:1) (right panel). Concentrations of BTN3A1 BFI shown in the upper panel are 6.25, 12.5, 25, 50, and 100 mMshown in gray. The kinetics fitting curves
are shown as black. In the lower panel, concentrations of BTN3A1 BFI shown are 3.75, 7.5, 15, 30, and 60 mMshown in gray. The kinetics fitting curves are shown
as black.
(E) Same experimental setup but with recombinant BTN3A1 B30.2 domain, lacking the N-terminal region connector to the transmembrane domain. In the left
panel, the interaction wasmeasured without cHDMAPP. Concentrations of BTN3A1 B30.2 shownwere 12.5, 25, 50, 100, and 200 mMshown in gray. The kinetics
fitting curves are shown as black. In the lower panel, the interaction wasmeasuredwith cHDMAPP (1:1). Concentrations of B30.2 domain shown are 3.75, 7.5, 15,
30, and 60 mM shown in gray. Data show one representative experiment.physiological circumstances (Ga´spa´r et al., 2001). Without ABP
stimulation, potent FRET efficiencies between stained mem-
brane and both antibodies were observed (Figure 6B), suggest-
ing that the BTN3 Ig-V domain is in close proximity to the cell1980 Cell Reports 15, 1973–1985, May 31, 2016membrane. Strikingly, however, treatment of cells with ABP
resulted in a marked reduction in FRET signals (Figure 6B),
demonstrating that intracellular phosphoantigen accumulation
associates with a conformational change of BTN3 molecules.
Figure 6. Intracellular Phosphoantigen
Accumulation Induces Extracellular Confor-
mational Changes in BTN3
(A) HEK293 cells were pretreated with medium, C3
transferase, and/or pamidronate, and the surface
membrane of cells was subsequently stained with
the fluorescent lipid conjugate BODIPY FL (FRET
donor), and BTN3 molecules were labeled with
mouse anti-CD277 monoclonal antibodies (mAbs)
originating either from clone 20.1 or from the clone
103.2 followed by staining with secondary Alexa-
Fluor-594-conjugated Fab fragment (GaM) (FRET
acceptor).
(B) FRET efficiency was measured by flow cy-
tometry, and data represent mean ± SEM of at
least three independent experiments in triplicate
samples. The statistical significance of data was
analyzed by Mann-Whitney test.This change involves a pronounced distancing of the Ig-V
domain from the cell membrane. Importantly, Rho-inhibitor C3-
transferase treatment (Figure S2F) of cells did not prevent
ABP-driven conformational changes of the BTN3A1 homodimer
(Figure 6B) indicating that this conformational change is inde-
pendent of the enzymatic activity of RhoB. These data provide
support for the hypothesis that increases in intracellular phos-
phoantigen levels can induce extracellular changes in BTN3A1
dimers that may act as, or contribute to a molecular signature
recognized by Vg9Vd2 TCRs.
DISCUSSION
The translation of tumor-reactive Vg9Vd2 T cells to clinical appli-
cations has proven challenging, due to a limited understanding
of the molecular mechanisms by which Vg9Vd2 T cells recognize
their targets. Important progress has been made in this area by
recent elegant reports identifying BTN3A1 as a phosphoantigen
sensor that plays a key role in the activation of Vg9Vd2 T cells
(Vavassori et al., 2013; Harly et al., 2012; Sandstrom et al.,
2014). These studies suggest, however, nearly opposing mech-
anisms for the exact role of BTN3A1 in this process. Unfortu-
nately, this contradiction makes it unclear how intracellular
phosphoantigen accumulation translates into extracellular sig-
natures that can be recognized by Vg9Vd2 TCRs and acts as a
barrier to the clinical development of Vg9Vd2 T cell-based ther-
apies. In this study, we provide insights to support a two-compo-
nentmechanism necessary to fully activate Vg9Vd2 TCR+ T cells.
We describe the critical role of the small GTPase RhoB in spatial
redistribution of BTN3A1, as well as conformational changes in
BTN3A1 at the tumor cell surface. We propose that ABP stimu-
lation induces activation of RhoB and its compartmentalization
to membrane proximal areas, where it can directly interact with
BTN3A1, as has been demonstrated for several other Rho
GTPases (Dunford et al., 2006; Kranenburg et al., 1997). While
biochemical activity of RhoB induces a close vicinity of RhoB
with BTN3A1 and membrane rearrangements of BTN3A1 di-
mers, phosphoantigens allow for a dissociation of RhoB from
BTN3A1 and conformational changes in BTN3A1 at the cellmembrane, which are then independent of RhoB activity. These
findings, based on the model of Vg9Vd2TCR-engineered CD4+
abT cells, are most likely transferrable to the recognition
of Vg9Vd2 T cells, as both populations have comparable activ-
ity against defined target cells as we recently demonstrated
(Marcu-Malina et al., 2011). However, we cannot exclude that
the modulating effect of RhoB for the recognition of tumor cells
by Vg9Vd2 T cells can be partially overcome by utilizing
Vg9Vd2TCRs of higher affinity, or additional co-stimulatory mol-
ecules (Gr€under et al., 2012). Together, these data suggest that
RhoB is a key actor in the cellular mechanisms that couple phos-
phoantigen accumulation to BTN3A1-mediated triggering of
Vg9Vd2 TCR+ T cell responses.
The intrinsic GTPase activity of RhoB that cycles between bio-
logically active GTP-bound and inactive GDP-bound confor-
mations enables the differential association with downstream
signaling pathways. As such, RhoB functions as a molecular
switch in diverse cellular processes, ranging from gene tran-
scription to the regulation of cytoskeletal changes and vesicle
transport (Prendergast, 2001). Our data provide several lines of
evidence that support a direct link between the mevalonate
pathway-dependent changes in RhoB activity in tumor cells,
cytoskeletal reorganization, and tumor cell-induced activation
of Vg9Vd2 TCR+ T cells. However, the biological activity of
RhoB seems to be partially genetically predetermined, as sug-
gested by our initial screening strategy, we could not identify a
direct genetic link of the surrogate marker SNP with RhoB activ-
ity. It is possible that differential SNPs found in recognized tumor
cells, with the frequency of around 70% in the normal population,
act as enhancer of a distant genomic region through chromatin
looping (Pombo and Dillon, 2015), and indirectly influence
RhoB activity. The importance of RhoB expression in the studied
cancer cell lines was further emphasized by the loss in prolifer-
ative activity of complete RhoB knockdowns. Although we
encountered a genetic block in a small subset of patients who
were largely non-responsive to Vg9Vd2 TCR+ T cell-mediated tu-
mor control, our results identified in RhoB a crucial link connect-
ing intracellular changes to the recognition of target cells by
Vg9Vd2 TCR+ T cells (Gober et al., 2003). These changes areCell Reports 15, 1973–1985, May 31, 2016 1981
Figure 7. Two-Component Mechanism in Tumor Cells that Leads to Activation of Vg9Vd2 TCR T Cells
Non-activating phase: no accumulation of phosphoantigens (pAg, yellow stars), which retains GDP-bound RhoB (red circles+GDP) from extranuclear areas.
Activating phase component I: accumulation of phosphoantigens is followed by more GTP-bound RhoB formation (red circles+GTP). GTP-bound RhoB un-
dergoes subcellular re-compartmentalization (black arrows) accumulating at extranuclear areas and facilitates spatial redistribution of BTN3A1 by promoting
cytoskeletal trapping (green lines) in the plasma membrane binding to the B30.2 domain proximal connector region (CR) of BTN3A1 (blue hexagon). Activating
phase component II: GTP-bound RhoB dissociates (black arrow) fromwhile pAg binds to the B30.2 domain of BTN3A1, which triggers a conformational change of
the extracellular region (ER) of BTN3A1 leading to Vg9Vd2 TCR T cell activation.induced by the accumulation of phosphoantigens occurring in
the majority of cancer cells.
Our data suggest that pAgs act differently in separate cell
compartments and support a two-componentmodel. A dysregu-
lated mevalonate pathway leads to the activation and relocation
of RhoB to the membrane-proximal connector region of the
BTN3A1 cytoplasmic tail, through a process requiring GTPase
activity (Figure 7). B30.2 domains have been reported to function
as scaffold modules by spatiotemporally sequestering signaling
proteins to distinct subcellular locations (Perfetto et al., 2013).
This interaction favors an enhanced submembranous cytoskel-
eton arrangement, which leads to the observed immobilization
of BTN3A1 at the cell surface, similar to its reported role inmodu-
lating membrane structures such as focal adhesions (Allal et al.,
2002; Vegaet al., 2012).Moreover, our data suggest a sequential,
second cascade of events in the transmembrane compartment,
which is necessary for recognition by a Vg9Vd2 TCR+ T cell:
RhoB dissociates from immobilized BTN3A1 most likely after1982 Cell Reports 15, 1973–1985, May 31, 2016phosphoantigen binding toB30.2 and the conformational change
in the extracellular domain of BTN3A1,which is then independent
of RhoB GTPase activity. Our data furthermore most likely impli-
cate the involvement of an additional protein in this molecular
complex, which is required for the recognition by Vg9Vd2 TCR,
as others (Gu et al., 2015) have suggested. This observation cor-
roborates data from crystallographic experiments using soluble
BTN3A1 domains, which revealed a pronounced flexibility of
BTN3A1 dimers correlating with treatment with the agonist 20.1
antibody, which can mimic phosphoantigen-induced stimulation
of Vg9Vd2 T cells (Palakodeti et al., 2012). Our proposed two-
componentmodel supports an ‘‘inside-out’’ mechanismof phos-
phoantigen signaling to Vg9Vd2 TCR+ T cells as others have
suggested (Palakodeti et al., 2012; Sandstrom et al., 2014),
whereby intracellular phosphoantigen accumulation is translated
into surface changes of BTN3A1 by RhoB.
Consistent with our observations, other recent data also
suggest that additional factors are likely to be involved in the
recognition of tumor cells by Vg9Vd2 TCR+ T cells. In particular,
transfer of human BTN3A1 alone to rodent cells, which are not
recognized by Vg9Vd2 T cells (Morita et al., 2007), was insuffi-
cient to sensitize cells toward recognition by Vg9Vd2 T cells
(Sandstrom et al., 2014). Instead, this sensitization required
co-transfer of a substantial proportion of the human chromo-
some 6 (Rian˜o et al., 2014; Vavassori et al., 2013), suggesting
that the combined presence of BTN3A1 and additional human
genes located on this chromosome is essential for facilitating
target cell recognition by Vg9Vd2 T cells. The human RhoB
gene locates to chromosome 2, and moreover, protein se-
quences of RhoB are fully conserved between human and ro-
dents. Thus, other human-specific genes that mediate activation
of Vg9Vd2 T cells are yet to be identified. These might include
GTPase activating proteins (GAPs) and guanine nucleotide ex-
change factors (GEFs), both of which coordinate actions that
regulate the balance between the active, GTP-bound state and
inactive, GDP-bound state of Rho GTPases (Rossman et al.,
2005; Moon and Zheng, 2003). However, none of the known reg-
ulators of Rho GTPase signaling locate to the region on chromo-
some 6 required to transfer Vg9Vd2 T cell susceptibility to rodent
cells. Identification of these missing factors linking RhoB and
BTN3A1 to target cell recognition by Vg9Vd2 TCR+ T cells is
therefore an important challenge for further elucidating the
molecular activation mechanisms of Vg9Vd2 TCR+ T cells.
The identification of RhoB as a mechanistic link between
transformation-associated dysregulation of the mevalonate
pathway and BTN3A1-dependent activation of Vg9Vd2 TCR+
T cells has important implications for cancer immunotherapeutic
concepts using Vg9Vd2 T cells or their TCRs. Our observations
strongly suggest the potential of Vg9Vd2 TCR+ T cell-mediated
immune interventions to target selectively the leukemic but not
the healthy stem cell fraction. Thereby, the divergent intracellular
distribution of RhoB among recognized and non-recognized
tumor cells may be used as a biological surrogate marker
for the identification of patients susceptible to Vg9Vd2 TCR+
T cell-mediated tumor cell killing. Second, although we have
not been able to provide a direct genetic link between themarker
SNP and the function of RhoB, our data strongly argue for a ge-
netic predisposition, which most likely acts via post-translational
regulation of RhoB, and partially explains why some patients do
not benefit from Vg9Vd2 TCR+ T cell-mediated tumor control.
Third, our data put RhoB forward as a key therapeutic target
for improving immunotherapy using Vg9Vd2 TCR+ T cells. In
contrast to BTN3A1, which is ubiquitously expressed on healthy
as well as malignant cells, the data presented here and else-
where (Prendergast, 2001) demonstrate that RhoB possesses
transformation-selective characteristics, such as spatial distri-
bution, and could therefore represent a more selective therapeu-
tic target compared to BNT3A1. Moreover, the mobilization of
Vg9Vd2 T cells in cancer patients using in vivo or ex vivo stimu-
lation protocols with ABPs such as zoledronate (Fournie´ et al.,
2013; Fisher et al., 2014; Scheper et al., 2013) is likely limited
by the poor pharmacokinetic profile of ABPs (Lin, 1996) and their
toxicity to T cells upon prolonged exposure (Wang et al., 2011).
Agents modulating RhoB GTPase activity could raise attractive
opportunities to complement currently pursued Vg9Vd2 TCR+
T cell-based therapies. In summary, with RhoB we provide akey molecule that regulates the ability of cancer cells to activate
Vg9Vd2 TCR+ T cells, by orchestrating BTN3A1 in the plasma
membrane. This knowledge will enable the pre-selection of
patients susceptible to Vg9Vd2 T cell based therapies and will
enhance the efficacy of such therapies.
EXPERIMENTAL PROCEDURES
Retroviral Transduction of TCRs
The Vg9Vd2TCR genes were transduced into abT cells using retroviral super-
natant from Phoenix-Ampho packaging cells that were transfected with
gag-pol, env, and pBullet retroviral constructs containing TCR genes.
Functional T Cell Assays
IFN-g ELISPOT was performed as 15,000 T cells and 50,000 target cells were
cocultured in nitrocellulose plates, and the number of spots was quantified
using ELISPOT Analysis Software.
Zygosity/SNP Correlation Analysis
Recognition of CEPH EBV-LCL lines by Vg9Vd2 TCR+ T cells was defined
in IFN-g ELIspots. Hypothetical zygosities for candidate genetic loci were
deduced using classical Mendelian inheritance patterns within CEPH family
pedigrees, where the influence of candidate alleles on Vg9Vd2 TCR-mediated
recognition was assumed to be dominant. Correlations of predicted zygosities
with HapMap SNP genotypes of CEPH individuals were calculated with the
software tool ssSNPer.
Confocal Microscopy and Data Analysis
Cells were allowed to attach onto poly-L-lysine-precoated coverslips andwere
permeabilized and stained with anti-RhoB antibody. Images were acquired
using a Zeiss confocal laser scanning microscope LSM 700. Ratios between
nuclear and extranuclear signal of RhoB was determined using ImageJ soft-
ware, using DAPI staining to mark nuclei.
Statistical Analysis
All experiments were repeated at least three times unless otherwise indicated.
All data were shown as mean ± SEM. Statistical significance was analyzed by
either Mann-Whitney or Kruskal-Wallis test and Dunn’s multiple comparison
test.
All patients or their legal guardians provided written informed consent.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.04.081.
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